Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Moxifloxacin Hydrochloride

FDA-approved product (tablet, oral), marketed as Avelox, Avelox In Sodium Chloride 0.8% In Plastic Container, Moxeza and 3 more.

Registered studies
50+
Lab records
54
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Moxifloxacin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial conjunctivitis
  • Bacterial disease
  • Chronic bronchitis
  • Eye infection
  • Infection
  • Pneumonia
  • Sinusitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fluoroquinolones
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01MA14; WHO ATC S01AE07

Repurposing investigation

Moxifloxacin Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA97.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli99.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae98.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis97.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • E. coli: measured active in 1 of 1 lab record
  • K. pneumoniae: measured active in 28 of 28 lab records
  • M. tuberculosis: measured active in 24 of 25 lab records
Open Moxifloxacin Hydrochloride in ChEMBL Registered studies below
Show the 54 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Moxifloxacin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants

    NCT04126343 · start 2019-10-23

    Registered record
    Registry ID
    NCT04126343
    Conditions
    Healthy Study Participants
    Interventions
    Padsevonil; Moxifloxacin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2019-10-23
    Completion
    2020-05-22
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Study Participants
    InterventionPadsevonil; Moxifloxacin; Placebo
    PhasePhase 1
    Registry statusTerminated

  • The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB

    NCT03830671 · start 2019-03-08

    Registered record
    Registry ID
    NCT03830671
    Conditions
    Multi-drug Resistant Tuberculosis
    Interventions
    18-month regimen containing 6 anti-TB drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-03-08
    Completion
    2022-06-08
    Enrolment
    515

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMulti-drug Resistant Tuberculosis
    Intervention18-month regimen containing 6 anti-TB drugs
    PhasePhase 4
    Registry statusCompleted

  • Adequate Duration of Antibiotic Treatment in Community-acquired Pneumonia With High Risk Class and Adequate Initial Clinical Response

    NCT03609099 · start 2019-02-15

    Registered record
    Registry ID
    NCT03609099
    Conditions
    Community-acquired Pneumonia
    Interventions
    Moxifloxacin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-02-15
    Completion
    2021-05-15
    Enrolment
    424

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity-acquired Pneumonia
    InterventionMoxifloxacin; Placebo
    PhasePhase 4
    Registry statusUnknown

  • Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose

    NCT03866369 · start 2019-01-17

    Registered record
    Registry ID
    NCT03866369
    Conditions
    Healthy Subjects
    Interventions
    Moxifloxacin; Placebo; Lanifibranor; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-01-17
    Completion
    2019-08-27
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionMoxifloxacin; Placebo; Lanifibranor; Placebo
    PhasePhase 1
    Registry statusCompleted

  • A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function

    NCT03657446 · start 2018-09-18

    Registered record
    Registry ID
    NCT03657446
    Conditions
    Healthy Subjects
    Interventions
    Clazosentan; Placebo; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-09-18
    Completion
    2018-10-26
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionClazosentan; Placebo; Moxifloxacin
    PhasePhase 1
    Registry statusCompleted

  • Fluoroquinolone Associated Disability

    NCT03535558 · start 2018-05-17

    Registered record
    Registry ID
    NCT03535558
    Conditions
    Bronchitis; Sinusitis; Urinary Tract Infections
    Interventions
    Fluoroquinolone (FQ); Azithromycin (AZ); Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-05-17
    Completion
    2018-12-31
    Enrolment
    239,306

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchitis; Sinusitis; Urinary Tract Infections
    InterventionFluoroquinolone (FQ); Azithromycin (AZ); Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination
    PhaseNot recorded
    Registry statusCompleted

  • A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects

    NCT04083833 · start 2018-02-07

    Registered record
    Registry ID
    NCT04083833
    Conditions
    TQT Study
    Interventions
    Tetrodotoxin; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-02-07
    Completion
    2018-03-24
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTQT Study
    InterventionTetrodotoxin; Placebos
    PhasePhase 1
    Registry statusCompleted

  • A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

    NCT03432884 · start 2018-01-25

    Registered record
    Registry ID
    NCT03432884
    Conditions
    Healthy Volunteers
    Interventions
    BGB-3111; Placebo; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-01-25
    Completion
    2018-04-16
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionBGB-3111; Placebo; Moxifloxacin
    PhasePhase 1
    Registry statusCompleted

  • Optimizing the Antibiotic Treatment of Uncomplicated Acute Appendicitis

    NCT03236961 · start 2017-04-03

    Registered record
    Registry ID
    NCT03236961
    Conditions
    Acute Appendicitis
    Interventions
    Ertapenem; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2017-04-03
    Completion
    2029-04-01
    Enrolment
    552

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Appendicitis
    InterventionErtapenem; Moxifloxacin
    PhaseNot applicable
    Registry statusActive not recruiting

  • Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)

    NCT02589782 · start 2017-01

    Registered record
    Registry ID
    NCT02589782
    Conditions
    Tuberculosis, Multidrug-Resistant; Extensively Drug-Resistant Tuberculosis; Tuberculosis, Pulmonary
    Interventions
    Bedaquiline; Pretomanid; Moxifloxacin; Linezolid; Clofazimine; Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2017-01
    Completion
    2022-08-05
    Enrolment
    552

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant; Extensively Drug-Resistant Tuberculosis; Tuberculosis, Pulmonary
    InterventionBedaquiline; Pretomanid; Moxifloxacin; Linezolid +2 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females

    NCT02792517 · start 2016-02-12

    Registered record
    Registry ID
    NCT02792517
    Conditions
    Headache, Migraine
    Interventions
    Erenumab; Ethynil Estradiol/Norgestimate Oral Contraceptive
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-02-12
    Completion
    2016-09-09
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeadache, Migraine
    InterventionErenumab; Ethynil Estradiol/Norgestimate Oral Contraceptive
    PhasePhase 1
    Registry statusCompleted

  • TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

    NCT02410772 · start 2016-01-25

    Registered record
    Registry ID
    NCT02410772
    Conditions
    Tuberculosis
    Interventions
    rifapentine; rifapentine and moxifloxacin; control
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01-25
    Completion
    2021-05
    Enrolment
    2,516

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionrifapentine; rifapentine and moxifloxacin; control
    PhasePhase 3
    Registry statusCompleted

  • Study of the Effects of Intravenous Exenatide on Cardiac Repolarization

    NCT02650479 · start 2016-01

    Registered record
    Registry ID
    NCT02650479
    Conditions
    Healthy Adult Male and Female Volunteers
    Interventions
    Exenatide; Placebo; Moxifloxacin; Palonosetron
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-01
    Completion
    2016-04
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Adult Male and Female Volunteers
    InterventionExenatide; Placebo; Moxifloxacin; Palonosetron
    PhasePhase 1
    Registry statusCompleted

  • A Thorough QT Study of Telotristat Etiprate

    NCT02155205 · start 2014-05

    Registered record
    Registry ID
    NCT02155205
    Conditions
    QT Interval
    Interventions
    Telotristat etiprate; Placebo; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-05
    Completion
    Not recorded
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionQT Interval
    InterventionTelotristat etiprate; Placebo; Moxifloxacin
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of the Effect of Benzonatate on QT Intervals Following Single Dose Administration of Benzonatate to Healthy Volunteers

    NCT02207699 · start 2014-05

    Registered record
    Registry ID
    NCT02207699
    Conditions
    Healthy Volunteers
    Interventions
    Benzonatate 200 mg; Benzonatate 800 mg; Moxifloxacin 400 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-05
    Completion
    2014-07
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionBenzonatate 200 mg; Benzonatate 800 mg; Moxifloxacin 400 mg; Placebo
    PhasePhase 1
    Registry statusCompleted